Efficacy and safety of the anti-IL-12/23 p40 monoclonal...

Annals of the Rheumatic Diseases 2014 / 06 Vol. 73; Iss. 6

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., Gottlieb, A. B., Perate, M., Whitman, M., Dooley, L. T., Alten, R., B
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
73
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2013-204655
Date:
June, 2014
File:
PDF, 1.34 MB
english, 2014
Conversion to is in progress
Conversion to is failed